A large database study of hospitalization charges and follow-up re-admissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2)

摘要

Data-selection flow chart for patients who underwent lumbar fusion-related procedures using V-CBA or rhBMP-2 during the initial procedure. Data for patients re-admitted during the 12-month follow-up period did not include those who may have received follow-up treatment outside of the Premier Healthcare System